4.3. Analysis.
Comparison 4: Rho kinase inhibitor + prostaglandin analog versus prostaglandin analog, Outcome 3: Conjunctival hyperemia as adverse event (per person‐month)*
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.